Milsaperidone (VHX-896) vs Risperidone (Risperdal)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Milsaperidone (VHX-896)
Marketed by Vanda Pharmaceuticals
NCT06494397 · Phase 1 · completed
Every participant in this trial received both VHX-896 and iloperidone, just in a different order, so there is no separate group that shows what happens without VHX-896, and nobody was blinded to which drug was being given at each stage. The trial measured drug levels in the blood to compare the two products, not any change in psychiatric symptoms, and results have not been posted yet.
No aligned efficacy figure on record for this race.
Risperidone (Risperdal)
Marketed by Johnson & Johnson
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: September 2027 · NCT04478838 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Milsaperidone (VHX-896) | Risperidone (Risperdal) |
|---|---|---|
| PANSS total, change | —Not reported | -16.5 vs -9.2−7.2 vs placeboNCT021095621 other result
|
| CGI-S, change | —Not reported | -0.9 vs -0.5−0.4 vs placeboNCT021095621 other result
|
| PANSS response | —Not reported | —Not posted · NCT00297388 |
| PSP, change | —Not reported | —Not posted · NCT00297388 |
| Relapse (% of patients) | —Not reported | —Not posted · NCT00297388 |
PANSS total, change
- Milsaperidone (VHX-896)
- —Not reported
- Risperidone (Risperdal)
- -16.5 vs -9.2−7.2 vs placeboNCT02109562
1 other result
- -15.4 vs -9.2 NCT02109562
CGI-S, change
- Milsaperidone (VHX-896)
- —Not reported
- Risperidone (Risperdal)
- -0.9 vs -0.5−0.4 vs placeboNCT02109562
1 other result
- -0.9 vs -0.5 NCT02109562
PANSS response
- Milsaperidone (VHX-896)
- —Not reported
- Risperidone (Risperdal)
- —Not posted · NCT00297388
PSP, change
- Milsaperidone (VHX-896)
- —Not reported
- Risperidone (Risperdal)
- —Not posted · NCT00297388
Relapse (% of patients)
- Milsaperidone (VHX-896)
- —Not reported
- Risperidone (Risperdal)
- —Not posted · NCT00297388
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Milsaperidone (VHX-896): no structured comparison results are available for Schizophrenia.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Milsaperidone (VHX-896): 0 of 4 rows · Risperidone (Risperdal): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Risperidone (Risperdal) |
|---|---|
| Dropout rate | 78.3%180 mg subcutaneousa NCT03978832 · Phase 4 · registry result, not featured evidence show 22 more results5.9%CT - Oral Ris NCT00333177 · Phase 4 · registry result, not featured evidence 0%CT - RLAI NCT00333177 · Phase 4 · registry result, not featured evidence 14.3%HBT - Oral Ris NCT00333177 · Phase 4 · registry result, not featured evidence 5.9%HBT - RLAI NCT00333177 · Phase 4 · registry result, not featured evidence 0% NCT01050582 · Phase 4 · registry result, not featured evidence 17.5% NCT01855074 · Phase 4 · registry result, not featured evidence 29.6% NCT00299702 · Phase 4 · registry result, not featured evidence 0%PALI ER Delayed Initiation NCT00535132 · Phase 4 · registry result, not featured evidence 0%PALI ER Immediate Initiation NCT00535132 · Phase 4 · registry result, not featured evidence 16.7% NCT00056498 · Phase 4 · registry result, not featured evidence 28.6%120 mg NCT02109562 · Phase 3 · registry result, not featured evidence 22.4%90 mg NCT02109562 · Phase 3 · registry result, not featured evidence —4 mg NCT04567524 · Phase 2 · registry result, not featured evidence 25%4 mg NCT04567524 · Phase 2 · registry result, not featured evidence —2 mg NCT04567524 · Phase 2 · registry result, not featured evidence 0%2 mg NCT04567524 · Phase 2 · registry result, not featured evidence 40%120 mg NCT01677377 · Phase 2 · registry result, not featured evidence 6.7%90 mg NCT01677377 · Phase 2 · registry result, not featured evidence 6.7%60 mg NCT01677377 · Phase 2 · registry result, not featured evidence 29.4%DLP-114 Alpha-4 (6-months) NCT04418466 · Phase 1/2 · registry result, not featured evidence 35.3%DLP-114 Alpha-7 (12-months) NCT04418466 · Phase 1/2 · registry result, not featured evidence 44% NCT01786239 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | 1.4%180 mg subcutaneousa NCT03978832 · Phase 4 · registry result, not featured evidence show 22 more results—CT - Oral Ris NCT00333177 · Phase 4 · registry result, not featured evidence —CT - RLAI NCT00333177 · Phase 4 · registry result, not featured evidence —HBT - Oral Ris NCT00333177 · Phase 4 · registry result, not featured evidence —HBT - RLAI NCT00333177 · Phase 4 · registry result, not featured evidence — NCT01050582 · Phase 4 · registry result, not featured evidence 1.3% NCT01855074 · Phase 4 · registry result, not featured evidence 0% NCT00299702 · Phase 4 · registry result, not featured evidence —PALI ER Delayed Initiation NCT00535132 · Phase 4 · registry result, not featured evidence —PALI ER Immediate Initiation NCT00535132 · Phase 4 · registry result, not featured evidence — NCT00056498 · Phase 4 · registry result, not featured evidence 1.7%120 mg NCT02109562 · Phase 3 · registry result, not featured evidence 0%90 mg NCT02109562 · Phase 3 · registry result, not featured evidence —4 mg NCT04567524 · Phase 2 · registry result, not featured evidence 0%4 mg NCT04567524 · Phase 2 · registry result, not featured evidence —2 mg NCT04567524 · Phase 2 · registry result, not featured evidence 0%2 mg NCT04567524 · Phase 2 · registry result, not featured evidence —120 mg NCT01677377 · Phase 2 · registry result, not featured evidence —90 mg NCT01677377 · Phase 2 · registry result, not featured evidence —60 mg NCT01677377 · Phase 2 · registry result, not featured evidence —DLP-114 Alpha-4 (6-months) NCT04418466 · Phase 1/2 · registry result, not featured evidence —DLP-114 Alpha-7 (12-months) NCT04418466 · Phase 1/2 · registry result, not featured evidence — NCT01786239 · Phase na · registry result, not featured evidence |
| Serious AEs | 4.3%180 mg subcutaneousa NCT03978832 · Phase 4 · registry result, not featured evidence show 22 more results18.8%CT - Oral Ris NCT00333177 · Phase 4 · registry result, not featured evidence 8.3%CT - RLAI NCT00333177 · Phase 4 · registry result, not featured evidence 8.3%HBT - Oral Ris NCT00333177 · Phase 4 · registry result, not featured evidence 0%HBT - RLAI NCT00333177 · Phase 4 · registry result, not featured evidence 0% NCT01050582 · Phase 4 · registry result, not featured evidence 1.3% NCT01855074 · Phase 4 · registry result, not featured evidence 17.3% NCT00299702 · Phase 4 · registry result, not featured evidence 4%PALI ER Delayed Initiation NCT00535132 · Phase 4 · registry result, not featured evidence 3.1%PALI ER Immediate Initiation NCT00535132 · Phase 4 · registry result, not featured evidence 3.3% NCT00056498 · Phase 4 · registry result, not featured evidence 0.9%120 mg NCT02109562 · Phase 3 · registry result, not featured evidence 0%90 mg NCT02109562 · Phase 3 · registry result, not featured evidence 0%4 mg NCT04567524 · Phase 2 · registry result, not featured evidence —4 mg NCT04567524 · Phase 2 · registry result, not featured evidence 0%2 mg NCT04567524 · Phase 2 · registry result, not featured evidence —2 mg NCT04567524 · Phase 2 · registry result, not featured evidence 6.7%120 mg NCT01677377 · Phase 2 · registry result, not featured evidence 0%90 mg NCT01677377 · Phase 2 · registry result, not featured evidence 0%60 mg NCT01677377 · Phase 2 · registry result, not featured evidence 0%DLP-114 Alpha-4 (6-months) NCT04418466 · Phase 1/2 · registry result, not featured evidence 7.1%DLP-114 Alpha-7 (12-months) NCT04418466 · Phase 1/2 · registry result, not featured evidence 0% NCT01786239 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | 180 mg subcutaneousa upper respiratory tract infection 13% blood prolactin increased 8.7% decreased appetite 8.7% NCT03978832 · Phase 4 · registry result, not featured evidence show 18 more resultsbmi increase normal/overweight to obese 31.3% ldl or triglyceride increase 25% prolactin related symptom 12.5% NCT00333177 · Phase 4 · registry result, not featured evidence bmi increase normal/overweight to obese 25% prolactin related symptom 16.7% ldl or triglyceride increase 8.3% NCT00333177 · Phase 4 · registry result, not featured evidence ldl or triglyceride increase 41.7% prolactin related symptom 16.7% bmi increase normal/overweight to obese 0% NCT00333177 · Phase 4 · registry result, not featured evidence bmi increase normal/overweight to obese 12.5% ldl or triglyceride increase 6.3% prolactin related symptom 6.3% NCT00333177 · Phase 4 · registry result, not featured evidence blood prolactin increased 0.8% drug ineffective 0.8% eye infection 0.8% NCT01050582 · Phase 4 · registry result, not featured evidence extrapyramidal disorder 1.3% NCT01855074 · Phase 4 · registry result, not featured evidence insomnia 26.3% tremor 21.8% anxiety 17.9% NCT00299702 · Phase 4 · registry result, not featured evidence constipation 9.1% insomnia 9.1% somnolence 8.1% NCT00535132 · Phase 4 · registry result, not featured evidence insomnia 9.2% headache 8.2% constipation 6.1% NCT00535132 · Phase 4 · registry result, not featured evidence 120 mg injection site pain 22.2% (placebo 19.5%) headache 15.4% (placebo 23.7%) weight increased 12.8% (placebo 3.4%) NCT02109562 · Phase 3 · registry result, not featured evidence 90 mg headache 17.4% (placebo 23.7%) injection site pain 15.7% (placebo 19.5%) weight increased 13% (placebo 3.4%) NCT02109562 · Phase 3 · registry result, not featured evidence 4 mg akathisia 25% diarrhoea 25% abdominal discomfort 0% NCT04567524 · Phase 2 · registry result, not featured evidence 2 mg alanine aminotransferase increased 25% weight increased 25% abdominal discomfort 0% NCT04567524 · Phase 2 · registry result, not featured evidence 120 mg cough 20% dyspepsia 20% weight increased 20% NCT01677377 · Phase 2 · registry result, not featured evidence 90 mg weight increased 33.3% headache 20% dyspepsia 13.3% NCT01677377 · Phase 2 · registry result, not featured evidence 60 mg weight increased 26.7% headache 20% rash 20% NCT01677377 · Phase 2 · registry result, not featured evidence arthralgia 21.4% weight increased 21.4% abdominal pain 14.3% NCT04418466 · Phase 1/2 · registry result, not featured evidence insomnia 21.4% implant site pain 14.3% injection site discomfort 14.3% NCT04418466 · Phase 1/2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Risperidone (Risperdal)
+ 24 further endpoints in the CSV export.
Bipolar Disorder
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Bipolar Disorder pipeline
Milsaperidone (VHX-896)
Marketed by Vanda Pharmaceuticals
NCT06494397 · Phase 1 · completed
Every participant in this trial received both VHX-896 and iloperidone, just in a different order, so there is no separate group that shows what happens without VHX-896, and nobody was blinded to which drug was being given at each stage. The trial measured drug levels in the blood to compare the two products, not any change in psychiatric symptoms, and results have not been posted yet.
No aligned efficacy figure on record for this race.
Risperidone (Risperdal)
Marketed by Johnson & Johnson
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2028 · NCT07665073 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Bipolar Disorder
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Milsaperidone (VHX-896): no structured comparison results are available for Bipolar Disorder.
Available safety results
Risperidone (Risperdal)
| Dropout rate | 0% NCT01050582 · Phase 4 · registry result, not featured evidence |
|---|---|
| Discontinued due to AEs | — NCT01050582 · Phase 4 · registry result, not featured evidence |
| Serious AEs | 0% NCT01050582 · Phase 4 · registry result, not featured evidence |
| Most frequent reported AEs | blood prolactin increased 0.8% drug ineffective 0.8% eye infection 0.8% NCT01050582 · Phase 4 · registry result, not featured evidence |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Milsaperidone (VHX-896)'s landscape · Risperidone (Risperdal)'s landscape